IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy.
Anal Cell Pathol (Amst). 2012;35(5-6):377-80. doi: 10.3233/ACP-2012-0066.
Telomerase, a fundamental marker of neoplastic transformation, is widely expressed in both premalignant intraepithelial lesions and in most malignant lesions of the uterine cervix. We determined telomerase activity (TA) in uterine cervix by Repeat Amplification Protocol (TRAP) in a series of 62 cases, 44 with benign diseases (inflammation and/or metaplasia and/or acanthosis) and 18 with cervical intraepithelial neoplasia (CIN). No significant differences in TA were observed between benign lesions (median AEU value 36, range 0-119) and CIN (median AEU value 30, range 0-65). Conversely, TA was significantly higher in subjects who showed CIN evolution (65 range 45-119) than in disease-free individuals (34 range 0-95, ρ = 0.017) and in 1 patient with a CIN2 lesion who relapsed after 5 years. Our results suggest that TA of the uterine cervix is capable of predicting CIN evolution or relapse, thus indicating its potential usefulness as a prognostic marker in clinical surveillance programs.
端粒酶是肿瘤转化的一个基本标志物,广泛表达于宫颈的癌前上皮内病变和大多数恶性病变中。我们通过重复扩增协议(TRAP)在一系列 62 例病例中检测了宫颈中端粒酶活性(TA),其中 44 例为良性疾病(炎症和/或化生和/或棘皮症),18 例为宫颈上皮内瘤变(CIN)。良性病变(中位数 AEU 值 36,范围 0-119)和 CIN(中位数 AEU 值 30,范围 0-65)之间的 TA 无显著差异。相反,表现为 CIN 进展的患者的 TA 显著高于无疾病个体(34,范围 0-95,ρ=0.017),也显著高于 1 例 5 年后 CIN2 病变复发的患者。我们的结果表明,宫颈 TA 能够预测 CIN 的进展或复发,因此表明其在临床监测方案中作为预后标志物的潜在用途。